At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 15 enrolled

Drug / intervention

Avelumab +1 moredrug

Likely dose

Avelumab 10mg/kgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03399552

NCT03399552Phase 2Completed

Compare CT.gov

An Efficacy and Safety Study of Avelumab Plus SBRT in Malignant Mesothelioma (MPM)

Memorial Sloan Kettering Cancer Center·interventional·Posted Jan 16, 2018·Updated Oct 23, 2023

In Brief

A Phase 2 clinical trial evaluating Avelumab and Stereotactic Body Radiation Therapy for Malignant Mesothelioma (MPM). Completed, enrolled 15 participants across 7 sites.

Detailed Summary

The purpose of this study is to find out whether the combination of avelumab and SBRT is safe and what effect avelumab has on mesothelioma when given in combination with SBRT. In addition, a goal of this protocol is to study the effect of radiation therapy on the immune system. It is thought that radiation treatment may create a form of 'vaccine' against cancer inside the body and immunotherapy may improve this effect. The combination of radiation treatment and immunotherapy may be more effective against cancer than either radiation or immunotherapy alone.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsMalignant Mesothelioma (MPM)

CountriesUnited States

CollaboratorsPfizer

Timeline

Phase 2CompletedFinished

201820192020202120222023202420252026

Enrollment StartDec 2017

First PostedJan 2018

Primary CompletionJan 2023

TodayJul 2026

First PostedJan 16, 2018

Enrollment StartDec 20, 2017

Primary CompletionJan 20, 2023

TodayJul 2, 2026

Enrollment to primary: 5.1 yearsPosted 8.5 years ago

Interventions

Avelumabdrug

10mg/kg delivered by IV infusion

Stereotactic Body Radiation Therapyradiation

short course of SBRT after the first two doses of avelumab